Abstract:BACKGROUND:Decoy receptor 3 (DcR3) has been reported to be involved in different cancers. However, few related researches have been accomplished on the role of DcR3 in lung cancer.OBJECTIVE:To explore the expression level and clinicopathological implication of DcR3 protein in lung cancer tissues.MATERIALS AND METHODS:Immunohistochemistry was used to examine DcR3 protein expression in lung cancer (n=365) and normal lung tissues (n=26). The relationships between DcR3 expression and clinical parameters were further investigated. Furthermore, the diagnostic and clinicopathological value of DcR3 mRNA was analyzed based on The Cancer Genome Atlas database in lung cancer patients.RESULTS:Compared to normal lung tissues, DcR3 expression was significantly higher in lung cancer (P=0.007) tissues, including small-cell lung cancer (P=0.001) and non-small-cell lung cancer (P=0.008). In addition, DcR3 expression was related to tumor-node-metastasis (TNM) stage (P<0.001), tumor diameter (P=0.007), distant metastasis (P<0.001), and lymph node metastasis (P<0.001) in lung cancers. When concerning non-small-cell lung cancer, consistent correlations between DcR3 expression and TNM stage (P<0.001), tumor diameter (P=0.019), distant metastasis (P<0.001), and lymph node metastasis (P<0.001) were found. Simultaneously, in small-cell lung cancer, TNM stage (P=0.004) and lymph node metastasis (P=0.005) were also associated with DcR3 expression. Additionally, receiver operator characteristic curve revealed that the area under curve (AUC) of DcR3 was 0.637 (95% confidence interval [CI] 0.531-0.742) for lung cancer. Furthermore, DcR3 was overexpressed in both adenocarcinoma and squamous cell carcinoma tissues than in noncancerous lung tissues (all P<0.0001) based on the data from The Cancer Genome Atlas. AUC of DcR3 was 0.726 (95% CI 0.644-0.788) for lung adenocarcinoma patients and 0.647 (95% CI 0.566-0.728) for squamous cell carcinoma patients. DcR3 expression was also related to the overall survival (P<0.001) and disease-free survival (P<0.001) of lung adenocarcinoma according to the data from The Cancer Genome Atlas.CONCLUSION:Our study confirms that DcR3 might be involved in the tumorigenesis and deterioration of lung cancer. Therefore, the detection of DcR3 gains the potential to be applied in the clinic for screening and progression prediction of lung cancer.

Clinical Significance of Decoy Receptor 3 Expression in Pancreatic Carcinoma

Decoy receptor 3 (DcR3) overexpression predicts the prognosis and pN2 in pancreatic head carcinoma

Clinical Significance of Expression and Amplification of the DcR3 Gene in Pancreatic Carcinomas.

Significance of Decoy Receptor 3 in Sera of Hepatocellular Carcinoma Patients

Expression and Clinicopathological Implication of DcR3 in Lung Cancer Tissues: a Tissue Microarray Study with 365 Cases.

Decoy Receptor 3 Expression in Esophageal Squamous Cell Carcinoma: Correlation with Tumour Invasion and Metastasis

Over-expression of decoy receptor 3 in gastric precancerous lesions and carcinoma.

Expression of decoy receptor 3 in liver tissue microarrays.

Decoy Receptor 3 (dcr3) As a Biomarker of Tumor Deterioration in Female Reproductive Cancers: A Meta-Analysis.

Silencing Of Decoy Receptor 3 (Dcr3) Expression By Sirna In Pancreatic Carcinoma Cells Induces Fas Ligand-Mediated Apoptosis In Vitro And In Vivo

Overexpression of DcR3 and Its Significance on Tumor Cell Differentiation and Proliferation in Glioma

High Dcr3 Expression Predicts Stage Pn2-3 in Gastric Cancer

[Overexpression and Genomic Amplification of Decoy Receptor 3 in Hepatocellular Carcinoma and Significance Thereof].

Expressions of DcR3 and caspase-3 and their significance in colorectal adenocarcinoma and precancerous lesions

Expression of DEK in Pancreatic Cancer and Its Correlation with Clinicopathological Features and Prognosis

Diagnostic Potential Of Serum Exosomal Colorectal Neoplasia Differentially Expressed Long Non-Coding Rna (Crnde-P) And Microrna-217 Expression In Colorectal Carcinoma

Correlations Between the Expression of Notch3 in Pancreatic Ductal Adenocarcinoma with Clinical Features and Overall Survival

Decoy Receptor 3 Suppresses FasL-induced Apoptosis Via ERK1/2 Activation in Pancreatic Cancer Cells

Overexpression of Decoy Receptor 3 in Hepatocellular Carcinoma and Its Association with Resistance to Fas Ligand-Mediated Apoptosis

The expression and clinical significance of DcR3 and Smad4 in gastric cancer

Clinical Significance of Decoy Receptor 3 Upregulation in Patients with Hepatitis B and Liver Fibrosis.